SCHEMBL7518345

SCHEMBL7518345

Cc1ccc(S(=O)(=O)n2c(-c3nc4cc(Cl)c(Cl)cc4[nH]3)cc3cc(C=C4SC(=O)NC4=O)ccc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.41
PIM1 P11309 4/20 0.41
PIM2 Q9P1W9 4/20 0.41
IGF1R P08069 1/20 0.41
PTPN1 P18031 1/20 0.38
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 3/20 0.36
PPARG P37231 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
POLB P06746 4/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
PIK3CD O00329 1/20 0.35
CSNK2A2 P19784 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7518342 1.00 HPGD (0.41) HPGDPIM1PIM2IGF1RPTPN1
SCHEMBL7514753 0.85 PTPN1 (0.38) HPGDPIM1PIM2IGF1RPTPN1
SCHEMBL7514741 0.85 PTPN1 (0.38) HPGDPIM1PIM2IGF1RPTPN1
SCHEMBL7513130 0.85 ESR1 (0.38) HPGDPTPN1MEN1KMT2AALDH1A1
SCHEMBL7516066 0.83 IGF1R (0.48) HPGDPIM1PIM2IGF1RHTT
SCHEMBL7516068 0.83 IGF1R (0.48) HPGDPIM1PIM2IGF1RHTT
SCHEMBL7520438 0.78 IGF1R (0.43) HPGDPIM1PIM2IGF1RMEN1
SCHEMBL7520443 0.78 IGF1R (0.43) HPGDPIM1PIM2IGF1RMEN1
SCHEMBL7519340 0.77 IGF1R (0.42) HPGDPIM1PIM2IGF1RPPARG
SCHEMBL7519343 0.77 IGF1R (0.42) HPGDPIM1PIM2IGF1RPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 HPGD 726/4885PIM1 1545/4885PIM2 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.